Premium
Lipella Pharmaceuticals Inc (LIPO)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinic... Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania. Show more
PITTSBURGH, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative...
PITTSBURGH, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious...
Patent application covers key technology innovations for delivering therapeutic agentsProprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer...
PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious...
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0509 | -12.0302528953 | 0.4231 | 0.4301 | 0.35 | 245063 | 0.40221197 | CS |
| 4 | -0.022 | -5.58092338914 | 0.3942 | 0.5145 | 0.35 | 2152812 | 0.43676204 | CS |
| 12 | -0.1208 | -24.5030425963 | 0.493 | 0.57 | 0.3234 | 1157435 | 0.44082967 | CS |
| 26 | -0.3408 | -47.7980364656 | 0.713 | 1.5 | 0.3234 | 2173440 | 0.78005296 | CS |
| 52 | -0.7478 | -66.7678571429 | 1.12 | 1.5 | 0.3234 | 1118761 | 0.78161863 | CS |
| 156 | -6.6478 | -94.698005698 | 7.02 | 7.72 | 0.3234 | 831921 | 1.29386095 | CS |
| 260 | -6.6478 | -94.698005698 | 7.02 | 7.72 | 0.3234 | 831921 | 1.29386095 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
